Mainstay's Update on Regulatory Application for ReActiv8 in Australia
Dublin, Ireland: 5 April 2018 - Mainstay Medical International plc (Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain, today provides an update on its application for the admission of ReActiv8 to the Australian Register of Therapeutic Goods (ARTG), which the Company filed in January 2017.
The Therapeutic Goods Administration (TGA) has requested additional clinical data with respect to ReActiv8. To provide the most meaningful clinical data possible, we intend to rely on the clinical data being gathered as part of the ongoing ReActiv8-B clinical study. As stated previously, this clinical study is expected to be fully enrolled by the end of the second quarter of 2018, with a full data readout expected towards the end of 2018. Upon availability of the ReActiv8-B data, we plan to submit a new application to the TGA seeking admission of ReActiv8.
More info on Mainstay Medical's website.
Next > TCR signs Partnership Agreement with the Telematics’ Supplier Sensolus
Previous > NGDATA sets up global AI Research Lab in Singapore